Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.80 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 4/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29803773 | 1.00 | NR1H2 (0.80) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL61143 | 0.89 | NR1H2 (0.90) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL29507781 | 0.89 | NR1H2 (1.00) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL308035 | 0.89 | NR1H2 (1.00) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL29377835 | 0.89 | NR1H2 (0.90) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL4924112 | 0.86 | NR1H2 (0.77) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL4928220 | 0.86 | NR1H2 (0.85) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL31730418 | 0.85 | NR1H2 (0.63) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL2056300 | 0.83 | ESR2 (0.58) | NR1H2ESR2HDAC1DDB1CRBN | |
| SCHEMBL1168098 | 0.83 | ESR2 (0.79) | NR1H2ESR2HDAC1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4702026-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-20 | — | — | US | disclosed |
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| CN-119923391-A | Targeted protein degradation of PARP14 for use in therapy | 艾伯维新加坡运营私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025071172-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER OR TUMORS COMPRISING SAME | 주식회사 대웅제약 | 2025-04-03 | — | — | WO | disclosed |
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-1474399-A1 | BENZENESULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2004-11-10 | — | — | EP | disclosed |
| EP-1470102-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-10-27 | — | — | EP | disclosed |
| US-20040063935-A1 | Aliphatic nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003068752-A1 | BENZENESULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068732-A2 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 AND D2 RECEPTOR LIGA DS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| US-20030149027-A1 | 1,5-benzodiazepine compounds, their production and use | OI SATORU (JP) | 2003-08-07 | — | — | US | disclosed |
| WO-2003064376-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-08-07 | — | — | WO | disclosed |
| EP-1325910-A1 | ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
| EP-1123928-A1 | 1,5-BENZODIAZEPINE COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND MEDICINE | Takeda Chemical Industries, Ltd. (JP) | 2001-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063935-A1 | Aliphatic nitrogenous five-membered ring compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SCN5A, CYP11B1 | NR1H2 166/4885ESR2 3580/4885HDAC1 267/4885 |
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | CD38, BCL9, BCL6B | NR1H2 314/4885ESR2 794/4885HDAC1 81/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | NR1H2 473/4885ESR2 764/4885HDAC1 725/4885 |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | SF1, SF3A1, SFXN1 | NR1H2 1253/4885ESR2 581/4885HDAC1 124/4885 |
| US-20030149027-A1 | 1,5-benzodiazepine compounds, their production and use | GABRA1, GABRA5, CNR1 | NR1H2 92/4885ESR2 814/4885HDAC1 402/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | NR1H2 470/4885ESR2 161/4885HDAC1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.